Barclays Reaffirms Underweight Rating for Definitive Healthcare (NASDAQ:DH)

Barclays reissued their underweight rating on shares of Definitive Healthcare (NASDAQ:DH) in a report issued on Monday, MarketBeat Ratings reports. Barclays currently has a $4.00 target price on the stock.

DH has been the subject of several other research reports. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research report on Friday, November 8th. BTIG Research initiated coverage on shares of Definitive Healthcare in a report on Tuesday, September 17th. They set a “buy” rating and a $7.00 target price for the company. Finally, Stephens started coverage on shares of Definitive Healthcare in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price target on the stock. Two analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, Definitive Healthcare has a consensus rating of “Hold” and an average price target of $5.72.

Definitive Healthcare Trading Up 1.5 %

Shares of Definitive Healthcare stock opened at $3.98 on Monday. The business has a fifty day simple moving average of $4.36 and a 200-day simple moving average of $4.51. Definitive Healthcare has a fifty-two week low of $3.19 and a fifty-two week high of $10.62. The firm has a market cap of $459.78 million, a price-to-earnings ratio of -1.28, a price-to-earnings-growth ratio of 3.14 and a beta of 1.41. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33.

Insider Buying and Selling at Definitive Healthcare

In other news, insider William Moschella sold 45,000 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total value of $211,500.00. Following the completion of the sale, the insider now directly owns 433,830 shares of the company’s stock, valued at $2,039,001. This represents a 9.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 14.84% of the company’s stock.

Institutional Investors Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 DIFC Ltd increased its position in Definitive Healthcare by 759.9% in the 3rd quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock worth $42,000 after purchasing an additional 8,215 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Definitive Healthcare in the 3rd quarter valued at approximately $55,000. Sanctuary Advisors LLC acquired a new position in Definitive Healthcare in the second quarter worth approximately $85,000. Bleakley Financial Group LLC bought a new position in Definitive Healthcare during the third quarter valued at approximately $74,000. Finally, Glenmede Trust Co. NA lifted its stake in Definitive Healthcare by 41.1% in the third quarter. Glenmede Trust Co. NA now owns 18,423 shares of the company’s stock valued at $82,000 after acquiring an additional 5,362 shares during the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.